[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @mike98572986 mike mike posts on X about $clpt, $qure, $clsb, victor the most. They currently have XXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1422364980339380240/interactions)  - X Week XXXXX +85% - X Month XXXXXX +33% - X Months XXXXXXX +273% - X Year XXXXXXX +7,712% ### Mentions: XX [#](/creator/twitter::1422364980339380240/posts_active)  - X Week XX +47% - X Month XX +13% - X Months XXX +1,013% - X Year XXX +1,279% ### Followers: XXX [#](/creator/twitter::1422364980339380240/followers)  - X Week XXX +2.90% - X Month XXX +53% - X Months XXX +229% - X Year XXX +440% ### CreatorRank: XXXXXXX [#](/creator/twitter::1422364980339380240/influencer_rank)  ### Social Influence [#](/creator/twitter::1422364980339380240/influence) --- **Social category influence** [social networks](/list/social-networks) XXXX% [technology brands](/list/technology-brands) XXXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% [finance](/list/finance) XXXX% [fashion brands](/list/fashion-brands) XXXX% [travel destinations](/list/travel-destinations) XXXX% **Social topic influence** [$clpt](/topic/$clpt) #1, [$qure](/topic/$qure) #4, [$clsb](/topic/$clsb) #2, [victor](/topic/victor) #1914, [phd](/topic/phd) #1194, [linkedin](/topic/linkedin) #558, [lets go](/topic/lets-go) 0.76%, [sung](/topic/sung) #1017, [asos](/topic/asos) 0.76%, [$cadl](/topic/$cadl) XXXX% **Top accounts mentioned or mentioned by** [@desertdweller93](/creator/undefined) [@doheenz](/creator/undefined) [@chrisbagmancap](/creator/undefined) [@aggie_cio](/creator/undefined) [@rahulsetty](/creator/undefined) [@frameworkwisely](/creator/undefined) [@nimesh3t](/creator/undefined) [@petermantas](/creator/undefined) [@adgrx5](/creator/undefined) [@nikkk1462560](/creator/undefined) [@moreinnerpeace](/creator/undefined) [@aintnothing1234](/creator/undefined) [@kumodongli](/creator/undefined) [@osarochester](/creator/undefined) [@mayoclinicneuro](/creator/undefined) [@mayoclinic](/creator/undefined) [@bernardbendokmd](/creator/undefined) [@profdollar](/creator/undefined) [@pythiar](/creator/undefined) [@biggercapital](/creator/undefined) **Top assets mentioned** [uniQure N.V. (QURE)](/topic/$qure) [Parachute (PAR)](/topic/$par) [BEAM (BEAM)](/topic/$beam) [Artificial Intelligence (AI4)](/topic/$ai4) ### Top Social Posts [#](/creator/twitter::1422364980339380240/posts) --- Top posts by engagements in the last XX hours "$clpt Neurona Lets go" [X Link](https://x.com/mike98572986/status/1975687620253667395) [@mike98572986](/creator/x/mike98572986) 2025-10-07T22:20Z XXX followers, 10.1K engagements "$clpt aadc Kebilidi gene therapy delivers big quality-of-life boost study finds While the one-time treatment has a high cost it leads to significant improvements in a patients quality of life and survival compared to the best standard of care. Researchers determined that Kebilidi delivers these substantial gains often measured in quality-adjusted life-years (QALYs) at a much lower cost relative to many other recently approved gene therapies for rare disorders. Substantial QALY gains were achieved with Kebilidi at a lower cost relative to many other rare and/or one-time treatments emphasizing" [X Link](https://x.com/mike98572986/status/1976204038594273372) [@mike98572986](/creator/x/mike98572986) 2025-10-09T08:32Z XXX followers, 1090 engagements "$qure $clpt Victor Sung He notes that following the recent uniQure news his clinic has received more than XX calls a day from people wanting to learn more. Hes excited about whats next after this landmark study" [X Link](https://x.com/mike98572986/status/1978240373274107932) [@mike98572986](/creator/x/mike98572986) 2025-10-14T23:23Z XXX followers, 7145 engagements "$clpt Clearpoint isnt part of the study but shows advantages of ICV delivery and is a brand new study regarding ICV delivery comparison To our knowledge a comprehensive comparison study of these two routes of delivery in large animals has not been done for ASOs. Therefore we conducted a study to compare the ICV and IT-L route of delivery for the MALAT1 ASO in dogs. We delivered the ASO and assessed biodistribution and RNA knockdown (KD) across CNS regions. We found that ICV delivery resulted in substantial bilateral distribution of the ASO and KD. Further we found that ICV delivery resulted" [X Link](https://x.com/mike98572986/status/1977785669864096036) [@mike98572986](/creator/x/mike98572986) 2025-10-13T17:17Z XXX followers, 1130 engagements "$clpt Askbio Interesting looks like they are testing some things to make the procedure quicker. This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform while providing similar amounts of drug to the part of the brain that needs treatment. Participants will receive a one-time infusion of AB-1005 directly into the putamen on each side of the brain. This is done during a surgical procedure under general anesthesia. The drug is delivered using a special technique called convection-enhanced delivery (CED)" [X Link](https://x.com/mike98572986/status/1977971045144617461) [@mike98572986](/creator/x/mike98572986) 2025-10-14T05:33Z XXX followers, 1357 engagements "$clpt $cadl can-3110 I would say the results were in the whatever category nothing great and nothing bad. Pretty much what would be expected. The Company today also reported updated survival data for all patients enrolled in the phase 1b clinical trial of CAN-3110 in rHGG. Updated median OS (mOS) was XXXX months (CI: 8.314.9) for arm A (n = 41) and XXXX months (CI: 10.0NA) for arm B (n = 9) respectively after a single injection of CAN-3110 consistent with previously reported data for arms A and B. At the time of data cutoff (8/15/2025) one patient from arm A and one patient from arm B were" [X Link](https://x.com/mike98572986/status/1978101976194834569) [@mike98572986](/creator/x/mike98572986) 2025-10-14T14:13Z XXX followers, 1086 engagements "$qure $clpt Huntingtons Win Leaves More Patients Willing to Test The conversations have changed in the last X weeks with the prospect of a treatment people are more inclined to want to know whether they are at risk of getting sick says Miedzybrodzka CEO Matt Kapusta says the company hasnt made any firm decisions about what to do outside the US yet. Article is about people in North Scotland since they have a very high Huntingtons rate compared to other parts of the world. Most hospitals in the U.K. lack the kind of specialized equipment for the procedure according to Miedzybrodzka" [X Link](https://x.com/mike98572986/status/1976693015218635194) [@mike98572986](/creator/x/mike98572986) 2025-10-10T16:55Z XXX followers, 1658 engagements "$qure $clpt No wonder Sung was going so crazy last time he spoke I always thought he had only X patients under his care. He was seeing it in real time and couldnt say a word. Will be interesting to hear what he says this Sunday now that he can speak. Seven of the XX high-dose participants were treated at UAB where neurologist Dr. Victor Sung director of the Division of Movement Disorders and the UAB Huntingtons Disease Clinic called the results a huge step toward changing the course of a disease long considered untreatable. There recent procedures are only taking in the 8-10 hour range" [X Link](https://x.com/mike98572986/status/1976797912777867462) [@mike98572986](/creator/x/mike98572986) 2025-10-10T23:52Z XXX followers, 3351 engagements "$clpt $CLSB laser and litt Additional comments regarding the malignant brain tumor study We are very pleased that the neurosurgeons who conducted the study found our system for neuro LITT procedures to be easy to use and that it performed very well. And even if this is a small study its very satisfying to see that the results are this good commented Dan J. Mogren CEO of CLS. For patients with glioblastoma having a minimally invasive option instead of open surgery is an important step forward. This may also provide new treatment options for many inoperable patients. Its less demanding for" [X Link](https://x.com/mike98572986/status/1975910745109061907) [@mike98572986](/creator/x/mike98572986) 2025-10-08T13:06Z XXX followers, 1748 engagements "$clpt program new paper Can-3110 The luck continues with clearpoint The serial samples showed that over time the drug changed the environment inside and around the tumor even though the tumor appeared to be progressing on magnetic resonance imaging (MRI) scans. This may happen because the immune system causes swelling and inflammation which can look like new or enlarging areas of contrast on a scan even when a tumor hasnt grown a phenomenon known as pseudoprogression. If CAN-3110 therapy can reshape the microenvironment and activate the immune system it may improve patient outcomes according" [X Link](https://x.com/mike98572986/status/1976066653004943686) [@mike98572986](/creator/x/mike98572986) 2025-10-08T23:26Z XXX followers, 5480 engagements "$clpt Trogenix interview with Dr Faye Robertson who will be leading the trial first human trial in fall of 2026 "As soon as I saw the incredibly exciting results from Professor Steve Pollard's lab I started working on how to bring this to a clinical trial for patients as quickly and safely as possible."" [X Link](https://x.com/mike98572986/status/1976456948313931868) [@mike98572986](/creator/x/mike98572986) 2025-10-10T01:17Z XXX followers, 1244 engagements "$clpt $rgnx RGX-121 "I am highly encouraged by the 12-month pivotal data and continued safety and efficacy profile of RGX-121" said Roberto Giugliani M.D. Ph.D. ProfessorDepartment of Genetics UFRGS Medical Genetics Service HCPAPorto Alegre Brazil."The vast majority of Hunter syndrome patients have no current treatment options to address the neurodevelopmental decline of this disease and are in urgent need of new therapies and a one-time treatment option like RGX-121 could make a meaningful impact on their lives."" [X Link](https://x.com/mike98572986/status/1963980489125220585) [@mike98572986](/creator/x/mike98572986) 2025-09-05T15:00Z XXX followers, 2047 engagements "$clpt cool article on James Wilson Highly recommend Instead of treating each therapy as a bespoke one-off product Wilson envisions a family of related programs built on the same scientific and manufacturing backbone. Wilson explained A platform is a group of similar diseases that can be treated using the same approachthe same capsid the same route the same dose the same manufacturingand just change the gene. Wilson has applied that logic directly to rare diseases. The incumbents pharma and biotech are not where a disruptive technology is going to be developed he said. Their goal is to sustain" [X Link](https://x.com/mike98572986/status/1976407649651655143) [@mike98572986](/creator/x/mike98572986) 2025-10-09T22:01Z XXX followers, 1729 engagements "$clpt Neurona He is part of the Neurona trial article also mentions they are working on a gene therapy wonder if clearpoint is involved in that" [X Link](https://x.com/mike98572986/status/1979167743506076126) [@mike98572986](/creator/x/mike98572986) 2025-10-17T12:48Z XXX followers, 1308 engagements "$qure $clpt Huntingtons Facebook group XXX votes XX percent yes on the question If a treatment for Huntingtons disease required brain surgery would you be willing to undergo it" [X Link](https://x.com/mike98572986/status/1974683885100548409) [@mike98572986](/creator/x/mike98572986) 2025-10-05T03:51Z XXX followers, 4200 engagements "$Clpt basically a commercial for clearpoint We love to see it" [X Link](https://x.com/mike98572986/status/1978293340123676897) [@mike98572986](/creator/x/mike98572986) 2025-10-15T02:54Z XXX followers, 3127 engagements "Adds today $Dcth and $par Really liking par tech down here" [X Link](https://x.com/mike98572986/status/1973060019521204520) [@mike98572986](/creator/x/mike98572986) 2025-09-30T16:19Z XXX followers, 1744 engagements "$clpt Askbio on LinkedIn From Seville to Honolulu to Vienna and beyond AskBio is engaging across the globe to advance pioneering science and manufacturing technology This week were proud to be present at three key scientific conferences: International Congress of Parkinsons Disease and Movement Disorders October XX Honolulu Hawaii Booth XXX 32nd Annual European Society of Gene and Cell Therapy Congress October 7-10 Seville Spain Booth 06/08 30th Annual International Congress of the World Muscle Society October XXX Vienna Austria Booth X Our teams are sharing and engaging on the potentially" [X Link](https://x.com/mike98572986/status/1975741895507886489) [@mike98572986](/creator/x/mike98572986) 2025-10-08T01:55Z XXX followers, XXX engagements "$clpt Bluerock Askbio The probability that gene therapy could create a completely breakthrough therapy is very high. It is a disease that manifests itself in the mid-50s early 60s. So clearly aging population increases the prevalence of the disease and we have seen the prevalence quite consistent across the world. So we see that the therapeutic value that this can bring for the Asian countries Australia and New Zealand would be very high he said. According to Pesquin Parkinson was a very appealing disease to generate the gene therapy. Like every new field you get your hits and misses. But I" [X Link](https://x.com/mike98572986/status/1977748837394776196) [@mike98572986](/creator/x/mike98572986) 2025-10-13T14:50Z XXX followers, 1708 engagements "$clpt $qure New presentation from Sarah Tabrizi minute XXXXX talks about uniqure procedure does say it is very complex they are getting it down to X hours and working on it. Working on shorter protocols. For children they can do it in 3-5 hours. Hour XX seconds talks about exon1 and why uniqure amt-130 is doing so well. @DesertDweller93 @Prof_Dollar @peter_mantas @PythiaR @biggercapital" [X Link](https://x.com/mike98572986/status/1974151998682562574) [@mike98572986](/creator/x/mike98572986) 2025-10-03T16:38Z XXX followers, 10.1K engagements "@adgrx5 Nah just was posting the story if it is clearpoint related I will always put the symbol" [X Link](https://x.com/mike98572986/status/1978507649495749115) [@mike98572986](/creator/x/mike98572986) 2025-10-15T17:05Z XXX followers, XX engagements "$clpt This is very smart and new trials definitely seem to be doing this. It should make approvals easier with more data that you can track. The more data you can show that is favorable the easier you can make your case to the FDA. Wearables and AI in Parkinsons trials: Enriching endpoints for accurate holistic assessments With the growth of wearables and AI/ML in areas like Parkinsons sponsors gain access to sensitive continuous digital biomarkers. Meanwhile data becomes more representative of the patients overall condition as opposed to a snapshot assessment skewed by daily fluctuations." [X Link](https://x.com/mike98572986/status/1978599806210892111) [@mike98572986](/creator/x/mike98572986) 2025-10-15T23:12Z XXX followers, 1059 engagements "$clpt For new people to the story X older interviews from Clearpoints CEO Joe Burnett The first was a interview from Oct 2024 Why he wanted to be a CEO And then the second thing I really realized is I loved working on what was coming next. And I was always you know really really passionate about hey how do we improve what's there And I wanted to be you know in the know. I wanted to know what was coming next what was going to be there you know two years five years ten years down the road. How he thinks about strategy But the first part is know your destination. Where is it that you want to go" [X Link](https://x.com/mike98572986/status/1977958119444734211) [@mike98572986](/creator/x/mike98572986) 2025-10-14T04:42Z XXX followers, 1372 engagements "$clpt MVX-220 AS New webinar Good probability it is a clearpoint program A Multi-Center Open-label Phase 1/2 Trial of the Safety and Efficacy of MVX-220 Gene Therapy Administered by Intra-Cisterna Magna Injection to Participants With Angelman Syndrome RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety and efficacy dose ranging study to determine whether RGX-121 is safe effective and well-tolerated by patients with MPS II. Intracisterna magna delivery Any program coming out of" [X Link](https://x.com/mike98572986/status/1978280826476662962) [@mike98572986](/creator/x/mike98572986) 2025-10-15T02:04Z XXX followers, 1730 engagements "Good reason for X and done programs $clpt Applies very strongly for a lot of their programs some programs there is nothing for the patients but some do have pills that help with certain symptoms and forgetting to take the pills is definitely a real thing and is a problem" [X Link](https://x.com/mike98572986/status/1976576066891423938) [@mike98572986](/creator/x/mike98572986) 2025-10-10T09:10Z XXX followers, 1700 engagements "$clpt not sure if clearpoint will be involved here but James Wilson has a long history of using clearpoint with his programs" [X Link](https://x.com/mike98572986/status/1975680607511597314) [@mike98572986](/creator/x/mike98572986) 2025-10-07T21:52Z XXX followers, XXX engagements "$clpt Bluerock Currently most of the cell therapies available to patients are autologous cell therapies which rely on modifying a patients own cells and then reintroducing them back to that same patient. While effective this approach significantly limits the number of patients who can be treated because the manufacturing must be done at a small scale. In contrast bemdaneprocel is an allogeneiccell therapy which starts with stem cells from a healthy donor that are re-engineered. Allogeneic cell therapies can be produced on a much larger scale" [X Link](https://x.com/mike98572986/status/1975737523893903844) [@mike98572986](/creator/x/mike98572986) 2025-10-08T01:38Z XXX followers, 1460 engagements "$Clpt clearpoint" [X Link](https://x.com/mike98572986/status/1978103050569974121) [@mike98572986](/creator/x/mike98572986) 2025-10-14T14:18Z XXX followers, 1614 engagements "Nice find $clpt $CLSB laser and litt English translation of the important parts as long as the translation is correct heh Hard-to-reach tumors The study shows that we can now successfully treat patients with hard-to-reach brain tumors. Previously we have not been able to do more for these patients because it entailed too great risks with operating in the traditional way says Peter Siesj chief physician in neurosurgery at Skne University Hospital adjunct professor at Lund University and the person responsible for the study. Faster recovery The alternative is traditional open surgery but with" [X Link](https://x.com/mike98572986/status/1978784544829641064) [@mike98572986](/creator/x/mike98572986) 2025-10-16T11:26Z XXX followers, 3861 engagements "A solid find $clpt if not following @Chrisbagmancap highly recommend" [X Link](https://x.com/mike98572986/status/1976373976910921791) [@mike98572986](/creator/x/mike98572986) 2025-10-09T19:47Z XXX followers, 4589 engagements "Impressive stuff Ive worked with these families for decades says Leone a professor of neuroscience and director of Rowan Universitys Cell and Gene Therapy Center. The results were seeing are impressive. Weve seen brain structures grow brain function improve; were seeing patients walk with minimal assistance. Their quality of life has completely changed. This is not the end but the beginning of a new era in the treatment of neurological disorders conditions that at their core involve impaired white matter she says noting that her ongoing research is motivated by the families affected by" [X Link](https://x.com/mike98572986/status/1978480731904258388) [@mike98572986](/creator/x/mike98572986) 2025-10-15T15:18Z XXX followers, XXX engagements "$clpt program new quotes about the study Can-3110 A new study led by Break Through Cancer's Accelerating Glioblastoma (GBM) Therapies Through Serial Biopsies TeamLab has revealed that an engineered virus therapy CAN-3110 triggered powerful immune responses deep inside glioblastoma tumors that were invisible to standard imaging like MRI according to early analyses of two patients with recurrent GBM. Not only was the procedure well tolerated in these patients but it also enabled an unprecedented level of insight into how tumors evolve during therapy. "This gives us a real-time window into what" [X Link](https://x.com/mike98572986/status/1976342411397022038) [@mike98572986](/creator/x/mike98572986) 2025-10-09T17:42Z XXX followers, 1389 engagements "$clpt aspen interview Cell & Gene: The Podcast So what differentiates us from other developers as you said in your introduction is that we are very heavily leveraging genomics bioinformatics artificial intelligence and machine learning to provide the highest quality cell therapy products for every patient which is specifically important when you do an autologous therapy where you derive cells personalized from each patient. And further we are also automating our manufacturing processes to increase the production capacity and reduce the costs of the manufacturing process to reach more patients" [X Link](https://x.com/mike98572986/status/1976384409860550820) [@mike98572986](/creator/x/mike98572986) 2025-10-09T20:28Z XXX followers, XXX engagements "$clpt $qure Awesome article on what the news means to the Huntingtons community "It is like winning the lottery XX times over" says Gemma XX. "I had accepted I would never get to grow old with my husband and that he might never see the kids become adults. That has all changed now." "I must have cried for three hours. Then the kids got home from school and I showed my daughter the BBC story and she burst into tears." "In some ways we are lucky he got past XX with no signs of it" says Gemma. "His mother died from the disease when she was XX. And now we have the prospect of a treatment. We have" [X Link](https://x.com/mike98572986/status/1971997364627165233) [@mike98572986](/creator/x/mike98572986) 2025-09-27T17:56Z XXX followers, 2510 engagements "$clpt $CLSB laser and litt If Im clearpoint I hire 1-2 more sales people for litt every day Im seeing articles of centers or hospitals posting about their 1st litt procedure completed. Litt seems to be going mainstream right about now. You got X players in the competition lots of studies in the last year and continues to be used for more and more things over time. I would get aggressive with going after it. It is clearly an avenue with a lot of open space. They got a lot of important things going on right now but this seems like an easy area to really go after" [X Link](https://x.com/mike98572986/status/1977068042275504562) [@mike98572986](/creator/x/mike98572986) 2025-10-11T17:45Z XXX followers, 1846 engagements "$qure $clpt Would love to hear peoples thoughts on these two topics how is the NFL data showing what it is showing if truly placebo humans technically can be tricked so I guess the 2nd point is weaker but would love to hear peoples thoughts on the NFL numbers. Agree if the drug wasnt working NFL would likely show that. I think out of all the data that is the most impressive one. Im curious what is the bearish argument on the nfl read out this is a genuine question what is the thesis on the nfl number showing that this isnt working I have trouble saying those numbers could be placebo I believe" [X Link](https://x.com/mike98572986/status/1979174419097620535) [@mike98572986](/creator/x/mike98572986) 2025-10-17T13:15Z XXX followers, 1830 engagements "$clpt Trogenix At the Mesa Trogenix CEO Ken Macnamara PhD explained to Inside Precision Medicine The unique precision comes from SSEsa genomic switch thats selective not just for a cell type but for the most aggressive cancer stem cell state. By integrating AI-driven discovery with synthetic biology Trogenix can rapidly design test and iterate candidate therapeutic AAVs. We can build and test hundreds of vectors in a living tissue context showing selectivity against patient-derived tumor samples said Macnamara. Were not just hitting the tumor corewere clearing infiltrating cells in the" [X Link](https://x.com/mike98572986/status/1978556523971588152) [@mike98572986](/creator/x/mike98572986) 2025-10-15T20:20Z XXX followers, XXX engagements "Lara Silverman post on LinkedIn $clpt #rare diseases Rare will get us there" The amazing session today on the n=1 gene therapy treatment of baby KJ emphasizes that the industry's focus on rare disease is actively saving lives right now today. Perhaps counterintuitively RDs actually have significant regulatory and clinical operation benefits when it comes to getting treatments to patients. The counterpoint is ARM's slide shown yesterday the emphasized the coming wave of prevalent disease products in CGT which strongly align with the new administration's focus on addressing major diseases at" [X Link](https://x.com/mike98572986/status/1975984967533707607) [@mike98572986](/creator/x/mike98572986) 2025-10-08T18:01Z XXX followers, 1569 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@mike98572986 mike
mike posts on X about $clpt, $qure, $clsb, victor the most. They currently have XXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX +85%
- X Month XXXXXX +33%
- X Months XXXXXXX +273%
- X Year XXXXXXX +7,712%
Mentions: XX #
- X Week XX +47%
- X Month XX +13%
- X Months XXX +1,013%
- X Year XXX +1,279%
Followers: XXX #
- X Week XXX +2.90%
- X Month XXX +53%
- X Months XXX +229%
- X Year XXX +440%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence social networks XXXX% technology brands XXXX% cryptocurrencies XXXX% finance XXXX% fashion brands XXXX% travel destinations XXXX%
Social topic influence $clpt #1, $qure #4, $clsb #2, victor #1914, phd #1194, linkedin #558, lets go 0.76%, sung #1017, asos 0.76%, $cadl XXXX%
Top accounts mentioned or mentioned by @desertdweller93 @doheenz @chrisbagmancap @aggie_cio @rahulsetty @frameworkwisely @nimesh3t @petermantas @adgrx5 @nikkk1462560 @moreinnerpeace @aintnothing1234 @kumodongli @osarochester @mayoclinicneuro @mayoclinic @bernardbendokmd @profdollar @pythiar @biggercapital
Top assets mentioned uniQure N.V. (QURE) Parachute (PAR) BEAM (BEAM) Artificial Intelligence (AI4)
Top Social Posts #
Top posts by engagements in the last XX hours
"$clpt Neurona Lets go"
X Link @mike98572986 2025-10-07T22:20Z XXX followers, 10.1K engagements
"$clpt aadc Kebilidi gene therapy delivers big quality-of-life boost study finds While the one-time treatment has a high cost it leads to significant improvements in a patients quality of life and survival compared to the best standard of care. Researchers determined that Kebilidi delivers these substantial gains often measured in quality-adjusted life-years (QALYs) at a much lower cost relative to many other recently approved gene therapies for rare disorders. Substantial QALY gains were achieved with Kebilidi at a lower cost relative to many other rare and/or one-time treatments emphasizing"
X Link @mike98572986 2025-10-09T08:32Z XXX followers, 1090 engagements
"$qure $clpt Victor Sung He notes that following the recent uniQure news his clinic has received more than XX calls a day from people wanting to learn more. Hes excited about whats next after this landmark study"
X Link @mike98572986 2025-10-14T23:23Z XXX followers, 7145 engagements
"$clpt Clearpoint isnt part of the study but shows advantages of ICV delivery and is a brand new study regarding ICV delivery comparison To our knowledge a comprehensive comparison study of these two routes of delivery in large animals has not been done for ASOs. Therefore we conducted a study to compare the ICV and IT-L route of delivery for the MALAT1 ASO in dogs. We delivered the ASO and assessed biodistribution and RNA knockdown (KD) across CNS regions. We found that ICV delivery resulted in substantial bilateral distribution of the ASO and KD. Further we found that ICV delivery resulted"
X Link @mike98572986 2025-10-13T17:17Z XXX followers, 1130 engagements
"$clpt Askbio Interesting looks like they are testing some things to make the procedure quicker. This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform while providing similar amounts of drug to the part of the brain that needs treatment. Participants will receive a one-time infusion of AB-1005 directly into the putamen on each side of the brain. This is done during a surgical procedure under general anesthesia. The drug is delivered using a special technique called convection-enhanced delivery (CED)"
X Link @mike98572986 2025-10-14T05:33Z XXX followers, 1357 engagements
"$clpt $cadl can-3110 I would say the results were in the whatever category nothing great and nothing bad. Pretty much what would be expected. The Company today also reported updated survival data for all patients enrolled in the phase 1b clinical trial of CAN-3110 in rHGG. Updated median OS (mOS) was XXXX months (CI: 8.314.9) for arm A (n = 41) and XXXX months (CI: 10.0NA) for arm B (n = 9) respectively after a single injection of CAN-3110 consistent with previously reported data for arms A and B. At the time of data cutoff (8/15/2025) one patient from arm A and one patient from arm B were"
X Link @mike98572986 2025-10-14T14:13Z XXX followers, 1086 engagements
"$qure $clpt Huntingtons Win Leaves More Patients Willing to Test The conversations have changed in the last X weeks with the prospect of a treatment people are more inclined to want to know whether they are at risk of getting sick says Miedzybrodzka CEO Matt Kapusta says the company hasnt made any firm decisions about what to do outside the US yet. Article is about people in North Scotland since they have a very high Huntingtons rate compared to other parts of the world. Most hospitals in the U.K. lack the kind of specialized equipment for the procedure according to Miedzybrodzka"
X Link @mike98572986 2025-10-10T16:55Z XXX followers, 1658 engagements
"$qure $clpt No wonder Sung was going so crazy last time he spoke I always thought he had only X patients under his care. He was seeing it in real time and couldnt say a word. Will be interesting to hear what he says this Sunday now that he can speak. Seven of the XX high-dose participants were treated at UAB where neurologist Dr. Victor Sung director of the Division of Movement Disorders and the UAB Huntingtons Disease Clinic called the results a huge step toward changing the course of a disease long considered untreatable. There recent procedures are only taking in the 8-10 hour range"
X Link @mike98572986 2025-10-10T23:52Z XXX followers, 3351 engagements
"$clpt $CLSB laser and litt Additional comments regarding the malignant brain tumor study We are very pleased that the neurosurgeons who conducted the study found our system for neuro LITT procedures to be easy to use and that it performed very well. And even if this is a small study its very satisfying to see that the results are this good commented Dan J. Mogren CEO of CLS. For patients with glioblastoma having a minimally invasive option instead of open surgery is an important step forward. This may also provide new treatment options for many inoperable patients. Its less demanding for"
X Link @mike98572986 2025-10-08T13:06Z XXX followers, 1748 engagements
"$clpt program new paper Can-3110 The luck continues with clearpoint The serial samples showed that over time the drug changed the environment inside and around the tumor even though the tumor appeared to be progressing on magnetic resonance imaging (MRI) scans. This may happen because the immune system causes swelling and inflammation which can look like new or enlarging areas of contrast on a scan even when a tumor hasnt grown a phenomenon known as pseudoprogression. If CAN-3110 therapy can reshape the microenvironment and activate the immune system it may improve patient outcomes according"
X Link @mike98572986 2025-10-08T23:26Z XXX followers, 5480 engagements
"$clpt Trogenix interview with Dr Faye Robertson who will be leading the trial first human trial in fall of 2026 "As soon as I saw the incredibly exciting results from Professor Steve Pollard's lab I started working on how to bring this to a clinical trial for patients as quickly and safely as possible.""
X Link @mike98572986 2025-10-10T01:17Z XXX followers, 1244 engagements
"$clpt $rgnx RGX-121 "I am highly encouraged by the 12-month pivotal data and continued safety and efficacy profile of RGX-121" said Roberto Giugliani M.D. Ph.D. ProfessorDepartment of Genetics UFRGS Medical Genetics Service HCPAPorto Alegre Brazil."The vast majority of Hunter syndrome patients have no current treatment options to address the neurodevelopmental decline of this disease and are in urgent need of new therapies and a one-time treatment option like RGX-121 could make a meaningful impact on their lives.""
X Link @mike98572986 2025-09-05T15:00Z XXX followers, 2047 engagements
"$clpt cool article on James Wilson Highly recommend Instead of treating each therapy as a bespoke one-off product Wilson envisions a family of related programs built on the same scientific and manufacturing backbone. Wilson explained A platform is a group of similar diseases that can be treated using the same approachthe same capsid the same route the same dose the same manufacturingand just change the gene. Wilson has applied that logic directly to rare diseases. The incumbents pharma and biotech are not where a disruptive technology is going to be developed he said. Their goal is to sustain"
X Link @mike98572986 2025-10-09T22:01Z XXX followers, 1729 engagements
"$clpt Neurona He is part of the Neurona trial article also mentions they are working on a gene therapy wonder if clearpoint is involved in that"
X Link @mike98572986 2025-10-17T12:48Z XXX followers, 1308 engagements
"$qure $clpt Huntingtons Facebook group XXX votes XX percent yes on the question If a treatment for Huntingtons disease required brain surgery would you be willing to undergo it"
X Link @mike98572986 2025-10-05T03:51Z XXX followers, 4200 engagements
"$Clpt basically a commercial for clearpoint We love to see it"
X Link @mike98572986 2025-10-15T02:54Z XXX followers, 3127 engagements
"Adds today $Dcth and $par Really liking par tech down here"
X Link @mike98572986 2025-09-30T16:19Z XXX followers, 1744 engagements
"$clpt Askbio on LinkedIn From Seville to Honolulu to Vienna and beyond AskBio is engaging across the globe to advance pioneering science and manufacturing technology This week were proud to be present at three key scientific conferences: International Congress of Parkinsons Disease and Movement Disorders October XX Honolulu Hawaii Booth XXX 32nd Annual European Society of Gene and Cell Therapy Congress October 7-10 Seville Spain Booth 06/08 30th Annual International Congress of the World Muscle Society October XXX Vienna Austria Booth X Our teams are sharing and engaging on the potentially"
X Link @mike98572986 2025-10-08T01:55Z XXX followers, XXX engagements
"$clpt Bluerock Askbio The probability that gene therapy could create a completely breakthrough therapy is very high. It is a disease that manifests itself in the mid-50s early 60s. So clearly aging population increases the prevalence of the disease and we have seen the prevalence quite consistent across the world. So we see that the therapeutic value that this can bring for the Asian countries Australia and New Zealand would be very high he said. According to Pesquin Parkinson was a very appealing disease to generate the gene therapy. Like every new field you get your hits and misses. But I"
X Link @mike98572986 2025-10-13T14:50Z XXX followers, 1708 engagements
"$clpt $qure New presentation from Sarah Tabrizi minute XXXXX talks about uniqure procedure does say it is very complex they are getting it down to X hours and working on it. Working on shorter protocols. For children they can do it in 3-5 hours. Hour XX seconds talks about exon1 and why uniqure amt-130 is doing so well. @DesertDweller93 @Prof_Dollar @peter_mantas @PythiaR @biggercapital"
X Link @mike98572986 2025-10-03T16:38Z XXX followers, 10.1K engagements
"@adgrx5 Nah just was posting the story if it is clearpoint related I will always put the symbol"
X Link @mike98572986 2025-10-15T17:05Z XXX followers, XX engagements
"$clpt This is very smart and new trials definitely seem to be doing this. It should make approvals easier with more data that you can track. The more data you can show that is favorable the easier you can make your case to the FDA. Wearables and AI in Parkinsons trials: Enriching endpoints for accurate holistic assessments With the growth of wearables and AI/ML in areas like Parkinsons sponsors gain access to sensitive continuous digital biomarkers. Meanwhile data becomes more representative of the patients overall condition as opposed to a snapshot assessment skewed by daily fluctuations."
X Link @mike98572986 2025-10-15T23:12Z XXX followers, 1059 engagements
"$clpt For new people to the story X older interviews from Clearpoints CEO Joe Burnett The first was a interview from Oct 2024 Why he wanted to be a CEO And then the second thing I really realized is I loved working on what was coming next. And I was always you know really really passionate about hey how do we improve what's there And I wanted to be you know in the know. I wanted to know what was coming next what was going to be there you know two years five years ten years down the road. How he thinks about strategy But the first part is know your destination. Where is it that you want to go"
X Link @mike98572986 2025-10-14T04:42Z XXX followers, 1372 engagements
"$clpt MVX-220 AS New webinar Good probability it is a clearpoint program A Multi-Center Open-label Phase 1/2 Trial of the Safety and Efficacy of MVX-220 Gene Therapy Administered by Intra-Cisterna Magna Injection to Participants With Angelman Syndrome RGX-121 is a gene therapy which is intended to deliver a functional copy of the iduronate-2-sulfatase gene (IDS) to the central nervous system. This study is a safety and efficacy dose ranging study to determine whether RGX-121 is safe effective and well-tolerated by patients with MPS II. Intracisterna magna delivery Any program coming out of"
X Link @mike98572986 2025-10-15T02:04Z XXX followers, 1730 engagements
"Good reason for X and done programs $clpt Applies very strongly for a lot of their programs some programs there is nothing for the patients but some do have pills that help with certain symptoms and forgetting to take the pills is definitely a real thing and is a problem"
X Link @mike98572986 2025-10-10T09:10Z XXX followers, 1700 engagements
"$clpt not sure if clearpoint will be involved here but James Wilson has a long history of using clearpoint with his programs"
X Link @mike98572986 2025-10-07T21:52Z XXX followers, XXX engagements
"$clpt Bluerock Currently most of the cell therapies available to patients are autologous cell therapies which rely on modifying a patients own cells and then reintroducing them back to that same patient. While effective this approach significantly limits the number of patients who can be treated because the manufacturing must be done at a small scale. In contrast bemdaneprocel is an allogeneiccell therapy which starts with stem cells from a healthy donor that are re-engineered. Allogeneic cell therapies can be produced on a much larger scale"
X Link @mike98572986 2025-10-08T01:38Z XXX followers, 1460 engagements
"$Clpt clearpoint"
X Link @mike98572986 2025-10-14T14:18Z XXX followers, 1614 engagements
"Nice find $clpt $CLSB laser and litt English translation of the important parts as long as the translation is correct heh Hard-to-reach tumors The study shows that we can now successfully treat patients with hard-to-reach brain tumors. Previously we have not been able to do more for these patients because it entailed too great risks with operating in the traditional way says Peter Siesj chief physician in neurosurgery at Skne University Hospital adjunct professor at Lund University and the person responsible for the study. Faster recovery The alternative is traditional open surgery but with"
X Link @mike98572986 2025-10-16T11:26Z XXX followers, 3861 engagements
"A solid find $clpt if not following @Chrisbagmancap highly recommend"
X Link @mike98572986 2025-10-09T19:47Z XXX followers, 4589 engagements
"Impressive stuff Ive worked with these families for decades says Leone a professor of neuroscience and director of Rowan Universitys Cell and Gene Therapy Center. The results were seeing are impressive. Weve seen brain structures grow brain function improve; were seeing patients walk with minimal assistance. Their quality of life has completely changed. This is not the end but the beginning of a new era in the treatment of neurological disorders conditions that at their core involve impaired white matter she says noting that her ongoing research is motivated by the families affected by"
X Link @mike98572986 2025-10-15T15:18Z XXX followers, XXX engagements
"$clpt program new quotes about the study Can-3110 A new study led by Break Through Cancer's Accelerating Glioblastoma (GBM) Therapies Through Serial Biopsies TeamLab has revealed that an engineered virus therapy CAN-3110 triggered powerful immune responses deep inside glioblastoma tumors that were invisible to standard imaging like MRI according to early analyses of two patients with recurrent GBM. Not only was the procedure well tolerated in these patients but it also enabled an unprecedented level of insight into how tumors evolve during therapy. "This gives us a real-time window into what"
X Link @mike98572986 2025-10-09T17:42Z XXX followers, 1389 engagements
"$clpt aspen interview Cell & Gene: The Podcast So what differentiates us from other developers as you said in your introduction is that we are very heavily leveraging genomics bioinformatics artificial intelligence and machine learning to provide the highest quality cell therapy products for every patient which is specifically important when you do an autologous therapy where you derive cells personalized from each patient. And further we are also automating our manufacturing processes to increase the production capacity and reduce the costs of the manufacturing process to reach more patients"
X Link @mike98572986 2025-10-09T20:28Z XXX followers, XXX engagements
"$clpt $qure Awesome article on what the news means to the Huntingtons community "It is like winning the lottery XX times over" says Gemma XX. "I had accepted I would never get to grow old with my husband and that he might never see the kids become adults. That has all changed now." "I must have cried for three hours. Then the kids got home from school and I showed my daughter the BBC story and she burst into tears." "In some ways we are lucky he got past XX with no signs of it" says Gemma. "His mother died from the disease when she was XX. And now we have the prospect of a treatment. We have"
X Link @mike98572986 2025-09-27T17:56Z XXX followers, 2510 engagements
"$clpt $CLSB laser and litt If Im clearpoint I hire 1-2 more sales people for litt every day Im seeing articles of centers or hospitals posting about their 1st litt procedure completed. Litt seems to be going mainstream right about now. You got X players in the competition lots of studies in the last year and continues to be used for more and more things over time. I would get aggressive with going after it. It is clearly an avenue with a lot of open space. They got a lot of important things going on right now but this seems like an easy area to really go after"
X Link @mike98572986 2025-10-11T17:45Z XXX followers, 1846 engagements
"$qure $clpt Would love to hear peoples thoughts on these two topics how is the NFL data showing what it is showing if truly placebo humans technically can be tricked so I guess the 2nd point is weaker but would love to hear peoples thoughts on the NFL numbers. Agree if the drug wasnt working NFL would likely show that. I think out of all the data that is the most impressive one. Im curious what is the bearish argument on the nfl read out this is a genuine question what is the thesis on the nfl number showing that this isnt working I have trouble saying those numbers could be placebo I believe"
X Link @mike98572986 2025-10-17T13:15Z XXX followers, 1830 engagements
"$clpt Trogenix At the Mesa Trogenix CEO Ken Macnamara PhD explained to Inside Precision Medicine The unique precision comes from SSEsa genomic switch thats selective not just for a cell type but for the most aggressive cancer stem cell state. By integrating AI-driven discovery with synthetic biology Trogenix can rapidly design test and iterate candidate therapeutic AAVs. We can build and test hundreds of vectors in a living tissue context showing selectivity against patient-derived tumor samples said Macnamara. Were not just hitting the tumor corewere clearing infiltrating cells in the"
X Link @mike98572986 2025-10-15T20:20Z XXX followers, XXX engagements
"Lara Silverman post on LinkedIn $clpt #rare diseases Rare will get us there" The amazing session today on the n=1 gene therapy treatment of baby KJ emphasizes that the industry's focus on rare disease is actively saving lives right now today. Perhaps counterintuitively RDs actually have significant regulatory and clinical operation benefits when it comes to getting treatments to patients. The counterpoint is ARM's slide shown yesterday the emphasized the coming wave of prevalent disease products in CGT which strongly align with the new administration's focus on addressing major diseases at"
X Link @mike98572986 2025-10-08T18:01Z XXX followers, 1569 engagements